July 8, 2009 - Covidien said today Health Canada approved the company’s abbreviated new drug submission (ANDS) for its kit for the preparation of technetium Tc 99m Sestamibi injection.
Covidien’s generic product is fully substitutable for Cardiolite, the company said.
With Health Canada approval of the ANDS, which was filed by the company’s Canadian subsidiary, Covidien’s generic product is expected to be available for customers in Canada this summer. The company’s generic product also is available in the U.S., the U.K., Denmark, Germany and Puerto Rico.
For more information: www.covidien.com
October 16, 2026 
